Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment
VL Martucci, K Pacak - Current problems in cancer, 2014 - Elsevier
Pheochromocytomas (PHEOs) are rare neuroendocrine tumors that arise from the
chromaffin cells of the adrenal glands. Paragangliomas (PGLs), the extra-adrenal …
chromaffin cells of the adrenal glands. Paragangliomas (PGLs), the extra-adrenal …
Pheochromocytoma and paraganglioma
K Pacak, SJ Wimalawansa - Endocrine Practice, 2015 - Elsevier
ABSTRACT Objective: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are
neural crest cell tumors associated with catecholamine production and assessed by a …
neural crest cell tumors associated with catecholamine production and assessed by a …
Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and …
I Janssen, EM Blanchet, K Adams, CC Chen… - Clinical Cancer …, 2015 - AACR
Purpose: Patients with succinate dehydrogenase subunit B (SDHB) mutation–related
pheochromocytoma/paraganglioma (PHEO/PGL) are at a higher risk for metastatic disease …
pheochromocytoma/paraganglioma (PHEO/PGL) are at a higher risk for metastatic disease …
PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma …
I Janssen, CC Chen, CM Millo, A Ling, D Taieb… - European journal of …, 2016 - Springer
Abstract Purpose Pheochromocytomas/paragangliomas (PPGLs) and their metastases are
tumors that predominantly express somatostatin receptor 2 (SSR2). 68 Ga-DOTA (0)-Tyr (3) …
tumors that predominantly express somatostatin receptor 2 (SSR2). 68 Ga-DOTA (0)-Tyr (3) …
SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma
Y Assadipour, SM Sadowski, M Alimchandani… - Surgery, 2017 - Elsevier
Background A staging/prognostic system has long been desired to better categorize
pheochromocytoma/paraganglioma which can be very aggressive in the setting of SDHB …
pheochromocytoma/paraganglioma which can be very aggressive in the setting of SDHB …
Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview
G De Filpo, M Maggi, M Mannelli, L Canu - Journal of Endocrinological …, 2021 - Springer
Background Metastatic pheochromocytomas and paragangliomas (PPGLs) occur in about 5–
26% of cases and are characterized by a heterogeneous prognosis. Metastases can be …
26% of cases and are characterized by a heterogeneous prognosis. Metastases can be …
Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies
Pheochromocytoma and paraganglioma (PCPGs) are rare neuroendocrine tumors that arise
from the chromaffin tissue of adrenal medulla and sympathetic ganglia. Although metastatic …
from the chromaffin tissue of adrenal medulla and sympathetic ganglia. Although metastatic …
68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a …
Y Kan, S Zhang, W Wang, J Liu, J Yang… - Acta …, 2018 - journals.sagepub.com
Background Metastatic pheochromocytoma and paraganglioma (PCs/PGLs) show high
germline mutation, and 18F-FDG and 68Ga-DOTA peptide positron emission …
germline mutation, and 18F-FDG and 68Ga-DOTA peptide positron emission …
Impact of extrinsic and intrinsic hypoxia on catecholamine biosynthesis in absence or presence of Hif2α in pheochromocytoma cells
N Bechmann, I Poser, V Seifert, C Greunke, M Ullrich… - Cancers, 2019 - mdpi.com
Pheochromocytomas and paragangliomas (PPGLs) with activated pseudohypoxic pathways
are associated with an immature catecholamine phenotype and carry a higher risk for …
are associated with an immature catecholamine phenotype and carry a higher risk for …
The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas
Objective: The aim of this study was to determine whether the genetic background of the
disease should be incorporated into treatment decision making. Background: Carotid body …
disease should be incorporated into treatment decision making. Background: Carotid body …